Briacell Therapeutics Company Insiders
| BCTX Stock | USD 0.54 0.02 3.41% |
Briacell Therapeutics' insiders are aggressively buying. The analysis of the overall insider sentiment regarding Briacell Therapeutics Corp suggests that vertually all insiders are extremely bullish. Briacell Therapeutics employs about 4 people. The company is managed by 4 executives with a total tenure of roughly 0 years, averaging almost 0.0 years of service per executive, having 1.0 employees per reported executive.
Briacell Therapeutics' Insider Buying Vs Selling
100
Selling | Buying |
Latest Trades
| 2022-12-28 | Jamieson Bondarenko | Acquired 28000 @ 4.58 | View | ||
| 2022-12-20 | Jamieson Bondarenko | Acquired 22000 @ 5.35 | View |
Monitoring Briacell Therapeutics' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Briacell |
Briacell Therapeutics Management Team Effectiveness
The company has return on total asset (ROA) of (1.2611) % which means that it has lost $1.2611 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.0601) %, meaning that it created substantial loss on money invested by shareholders. Briacell Therapeutics' management efficiency ratios could be used to measure how well Briacell Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to rise to 5.08 in 2024, despite the fact that Return On Tangible Assets are likely to grow to (0.64). At this time, Briacell Therapeutics' Total Assets are fairly stable compared to the past year. Non Currrent Assets Other is likely to rise to about 1.3 M in 2024, whereas Non Current Assets Total are likely to drop slightly above 1.2 M in 2024.Common Stock Shares Outstanding is likely to rise to about 17.3 M in 2024, despite the fact that Net Loss is likely to grow to (22.9 M).
Briacell Therapeutics Workforce Comparison
Briacell Therapeutics Corp is currently under evaluation in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 1,847. Briacell Therapeutics adds roughly 0.0 in number of employees claiming only tiny portion of equities under Health Care industry.
Briacell Therapeutics Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Briacell Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Briacell Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Briacell Therapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Schmieg Martin E. a day ago Disposition of 50000 shares by Schmieg Martin E. of Briacell Therapeutics at 8.47 subject to Rule 16b-3 | ||
Embro-pantalony Vaughn C. over a month ago Disposition of 50000 shares by Embro-pantalony Vaughn C. of Briacell Therapeutics at 8.47 subject to Rule 16b-3 | ||
Williams Williams V. over three months ago Disposition of 27272 shares by Williams Williams V. of Briacell Therapeutics at 5.31 subject to Rule 16b-3 | ||
Lustig Marc over six months ago Acquisition by Lustig Marc of 902935 shares of Briacell Therapeutics at 2.11 subject to Rule 16b-3 | ||
Williams Williams V. over six months ago Disposition of 22300 shares by Williams Williams V. of Briacell Therapeutics at 8.47 subject to Rule 16b-3 | ||
Williams William V over six months ago Purchase by Williams William V of 2530 shares of Briacell Therapeutics | ||
Williams William V over a year ago Briacell Therapeutics exotic insider transaction detected |
Briacell Therapeutics Notable Stakeholders
A Briacell Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Briacell Therapeutics often face trade-offs trying to please all of them. Briacell Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Briacell Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| William MD | President CEO | Profile | |
| MD FACP | Principal Founder | Profile | |
| Miguel LopezLago | Chief Officer | Profile | |
| MD MPH | Chief Officer | Profile |
About Briacell Therapeutics Management Performance
The success or failure of an entity such as Briacell Therapeutics often depends on how effective the management is. Briacell Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Briacell management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Briacell management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.68) | (0.64) | |
| Return On Capital Employed | (1.06) | (1.11) | |
| Return On Assets | (0.67) | (0.64) | |
| Return On Equity | 4.84 | 5.08 |
Please note, the imprecision that can be found in Briacell Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Briacell Therapeutics Corp. Check Briacell Therapeutics' Beneish M Score to see the likelihood of Briacell Therapeutics' management manipulating its earnings.
Briacell Therapeutics Workforce Analysis
Traditionally, organizations such as Briacell Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Briacell Therapeutics within its industry.Briacell Therapeutics Manpower Efficiency
Return on Briacell Therapeutics Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 1.2M | |
| Net Loss Per Executive | 1.2M |
Additional Tools for Briacell Stock Analysis
When running Briacell Therapeutics' price analysis, check to measure Briacell Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Briacell Therapeutics is operating at the current time. Most of Briacell Therapeutics' value examination focuses on studying past and present price action to predict the probability of Briacell Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Briacell Therapeutics' price. Additionally, you may evaluate how the addition of Briacell Therapeutics to your portfolios can decrease your overall portfolio volatility.